Successful Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment in a HIV Patient With Swallowing Difficulties

Abstract

Get full access to this article

View all access options for this article.

References

Schiele

Quinzler

Klimm

Pruszydlo

Haefeli

. Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms. Eur J Clin Pharmacol. 2013;69:937-948. doi:10.1007/s00228-012-1417-0

San

Lê

Matheron

, et al. Management of oral antiretroviral administration in patients with swallowing disorders or with an enteral feeding tube. Med Mal Infect. Published online November 10, 2019. doi:10.1016/j.medmal.2019.10.010

Foisy

Hughes

. Oral antiretroviral/HCV DAA administration: information on crushing and liquid drug formulations. Accessed June 7, 2020. https://www.hivclinic.ca/main/drugs_extra_files/Crushing%20and%20Liquid%20ARV%20Formulations.pdf

Lozano

Chueca

de Salazar

, et al. Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient. Antiviral Res. 2020;179:104717. doi:10.1016/j.antiviral.2020.104717

Fulco

. Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with esophageal cancer. Am J Health Syst Pharm. 2020;77:509-510. doi:10.1093/ajhp/zxaa017